Science Explorer Back to mapMap

Most cited papers from Vanquish Oncology (United States)

What are the most cited papers from Vanquish Oncology (United States)?

The most cited paper from Vanquish Oncology (United States) is "Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies" (Oana Cristina Danciu, Matthias Holdhoff, Richard A. Peterson et al., 2022), with 30 citations. Next come "The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma" (8) and "Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas" (7).

Showing 3 of 3 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies Oana Cristina Danciu, Matthias Holdhoff, Richard A. Peterson et al. · British Journal of Cancer Open access 5 Dec 2022 30
2 The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma Matthew W. Boudreau, Emily J. Tonogai, Claire P. Schane et al. · Melanoma Research Open access 22 Sep 2023 8
3 Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas Matthias Holdhoff, Martin Kelly Nicholas, Richard A. Peterson et al. · Neuro-Oncology Advances Open access 2023 7

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.